Medicinal Plant Research 2025, Vol.15, No.4, 188-196 http://hortherbpublisher.com/index.php/mpr 196 Yang C., Pan Q., Ji K., Tian Z., Zhou H., Li S., Luo C., and Li J., 2023, Review on the protective mechanism of astragaloside IV against cardiovascular diseases, Frontiers in Pharmacology, 14: 1187910. https://doi.org/10.3389/fphar.2023.1187910 Zang Y., Wan J., Zhang Z., Huang S., Liu X., and Zhang W., 2020, An updated role of astragaloside IV in heart failure, Biomedicine & Pharmacotherapy, 126: 110012. https://doi.org/10.1016/j.biopha.2020.110012 Zhai P., Chen Q., Wang X., Ouyang X., Yang M., Dong Y., Li J., Li Y., Luo S., Liu Y., Cheng X., Zhu R., and Hu D., 2024, The combination of Tanshinone IIA and astragaloside IV attenuates myocardial ischemia-reperfusion injury by inhibiting the STING pathway, Chinese Medicine, 19: 908. https://doi.org/10.1186/s13020-024-00908-y Zhang L., Shergis J., Yang L., Zhang A., Guo X., Zhang L., Zhou S., Zeng L., Mao W., and Xue C., 2019, Astragalus membranaceus (Huang Qi) as adjunctive therapy for diabetic kidney disease: An updated systematic review and meta-analysis, Journal of Ethnopharmacology, 239: 111921. https://doi.org/10.1016/j.jep.2019.111921 Zhang X., Qu H., Yang T., Liu Q., and Zhou H., 2022, Astragaloside IV attenuate MI-induced myocardial fibrosis and cardiac remodeling by inhibiting ROS/caspase-1/GSDMD signaling pathway, Cell Cycle, 21: 2309-2322. https://doi.org/10.1080/15384101.2022.2093598 Zheng Q., Zhuang Z., Wang Z., Deng L., Jin W., Huang Z., Zheng G., and Wang Y., 2020, Clinical and preclinical systematic review of Astragalus membranaceus for viral myocarditis, Oxidative Medicine and Cellular Longevity, 2020: 1560353. https://doi.org/10.1155/2020/1560353 Zheng Y., Ren W., Zhang L., Zhang Y., Liu D., and Liu Y., 2020, A review of the pharmacological action of Astragalus polysaccharide, Frontiers in Pharmacology, 11: 349. https://doi.org/10.3389/fphar.2020.00349
RkJQdWJsaXNoZXIy MjQ4ODYzNA==